Algernon Pharmaceuticals Invited to Present Phase 2 IPF and Chronic Cough Study Data at 9th American Cough Conference Post published:August 3, 2022 Post category:Press Release
Algernon Pharmaceuticals Reports Additional Positive Data From its Phase 2 Study of Ifenprodil for IPF and Chronic Cough Post published:July 30, 2022 Post category:Press Release
Algernon Pharmaceuticals Hits Co-Primary Endpoint in its Phase 2 Study of Ifenprodil for Idiopathic Pulmonary Fibrosis and Chronic Cough Post published:July 19, 2022 Post category:Press Release
Algernon Pharmaceuticals Provides Update on its Planned Phase 1 Repirinast Chronic Kidney Disease Study Post published:July 12, 2022 Post category:Press Release
Algernon Pharmaceuticals Provides Update on Its Phase 1 DMT Stroke Study Post published:July 7, 2022 Post category:Press Release
Algernon Pharmaceuticals Discloses Novel DMT Salt Patent Strategy Includes Bioactive Nicotinate and Pamoate Post published:July 7, 2022 Post category:Press Release
Algernon Pharmaceuticals Announces Pricing of Public Offering of Units Post published:June 29, 2022 Post category:Press Release
Algernon Pharmaceuticals Announces Issuance of Patent for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis Post published:June 22, 2022 Post category:Press Release
Algernon Pharmaceuticals Discloses Novel Salt Patent Strategy as Part of its Psychedelic Drug DMT Intellectual Property Post published:January 24, 2022 Post category:Press Release
Algernon Pharmaceuticals Files for Clinical Trial and Ethics Approval for Phase 1 DMT Human Stroke Study Post published:January 19, 2022 Post category:Press Release